指南与共识慢性肾脏病遗传性与小管间质肾病

常染色体显性多囊肾病治疗:整合临床指南、患者视角与真实世界效果

Treatment of Autosomal Dominant Polycystic Kidney Disease: Integrating Clinical Practice Guidelines, Patient Perspectives, and Real-World Effectiveness.
指南 / 共识 · J Am Soc Nephrol · 2026-04-02

常染色体显性多囊肾病(ADPKD)是需终身多学科管理的遗传性系统性疾病,约半数患者60岁前进展至肾衰竭。遗传学、影像学与病理生理学进展促成托伐普坦等疾病修饰疗法的早期诊断与风险分层应用。本叙述性综述整合临床指南、患者视角与真实世界数据,提出克服实践障碍的策略以促进指南落地。

要点

  • ADPKD约半数患者60岁前进展至肾衰竭,需终身多学科管理。
  • 托伐普坦等疾病修饰疗法适用于高风险患者,需早期诊断与风险分层。
  • 真实世界实施受疾病异质性、心理社会影响和个体化需求制约。

核心结论

  • 整合患者视角与真实世界效果有助于克服ADPKD指南实施中的实践障碍。

研究设计与样本

  • 叙述性综述,整合临床实践指南、患者视角与真实世界有效性证据。

主要发现

  • 约半数ADPKD患者60岁前进展至肾衰竭。
  • 托伐普坦等疾病修饰疗法已用于高风险患者。
  • 疾病异质性、心理社会影响和个体化需求阻碍指南真实世界实施。

关键数值与推荐

  • 高风险ADPKD患者可考虑托伐普坦等疾病修饰疗法。

临床怎么用

  • 应结合患者视角与真实世界证据个体化实施ADPKD指南以克服实践障碍。

局限性

  • 叙述性综述,未提供系统检索或定量合并方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autosomal dominant polycystic kidney disease is a systemic, hereditary disorder requiring life-long, multidisciplinary management. Approximately half of affected individuals progress to kidney failure by age 60 years. Recent advances in genetics, imaging, and disease pathophysiology have enabled earlier diagnosis and improved risk stratification and led to the development of disease-modifying therapies (such as tolvaptan) for high-risk patients. Despite the availability of comprehensive clinical practice guidelines, real-world implementation is hindered by disease heterogeneity, psychosocial impacts, and the need for individualized care. The aim of this narrative review is to facilitate guideline implementation by integrating evidence from patient perspectives and real-world effectiveness and offering strategies to overcome practical barriers.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Rangan G. Treatment of Autosomal Dominant Polycystic Kidney Disease: Integrating Clinical Practice Guidelines, Patient Perspectives, and Real-World Effectiveness. J Am Soc Nephrol. 2026. PMID: 41926217. doi:10.1681/ASN.0000001113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。